Hepatic Lesion Risk Analysis of Yangxueshengfa Capsule

Abstract

Abstract: By reviewing the relevant references and reports of the adverse drug reaction cases of Yangxueshengfa capsule in China, the post-marketing safety and risks(hepatic lesion) in post-marketing period of Yangxueshengfa capsule were reevaluated in this article. Risk management measures according to the characteristics of medicine were put forward. Suggestions were proposed for a safe and rational use of this medicine.

Key words: Yangxueshengfa capsule, safety and risk analysis, measure

CLC Number:

R282

YANG Le ,GUO Xiao-xin ,SONG Hai-bo. Hepatic Lesion Risk Analysis of Yangxueshengfa Capsule [J]. Chinese Journal of Pharmacovigilance, 2013, 10(6): 362-365.

References

[1] 李云富,耿秀双.养血生发胶囊致严重肝脏损害1 例[J].中国煤炭工业医学杂志,2008,11(12):1940.
[2] 刘绍莉.养血生发胶囊致药物性肝炎1 例[J].中国医院药学杂志,2006,26(12):1584.
[3] 霍敏英, 凌世华. 首乌片、养血生发胶囊同服引起肝炎[J].药物不良反应杂志, 2004, 6 (5) : 335-336.
[4] 郑丽娜,孙蓉.养血生发胶囊的现代药理与毒理学研究进展[J].中国药物警戒,2011,8(2):109-110.
[5] 李晓宇,孙蓉,吕莉莉. 养血生发胶囊对小鼠肝毒性“量- 时-毒”关系研究[J].中国药物警戒,2011,8(4):204-207.
[6] 吕莉莉,谢元璋,钱晓路,等.养血生发胶囊对小鼠肝毒性“量-时-毒”关系的病理学研究[J].中国药物警戒,2011,8(4):202-204.
[7] 胡锡琴,杨红莲,张晓琴,等. 制何首乌对大鼠肝脏毒理的实验研究[J].陕西中医学院学报,2006,29（3）：40-41.
[8] Kyoung Ah Jung, Hyun Ju Min, Seung Suk Yoo, et al. Drug-Induced Liver Injury: Twenty Five Cases of Acute Hepatitis Following Ingestion of Polygonum multifl orum Thunb[J]. Gut Liver,2011 ,5(4):493-499.
[9] 李剑,李优军. 何首乌致药物性肝炎11 例临床分析[J].实用医药杂志,2006,23（5）：573-574.
[10]郑丽娜,任海勇,张作平,等.HPLC法测定养血生发胶囊中二苯乙烯苷、大黄素、大黄素甲醚的含量[J].中国药物警戒,2011,8(4):200.
[11] Panis B, Wong DR, Hooymans P M, et al. Recurrent toxic hepatitis in a Caucasian girl related to the use of Shou-Wu-Pian, a Chinese herbal preparation[J]. J Pediatr Gastroenterol Nutr,2005,41(2):256-8.
[12]张敏.何首乌对肝脏损害的物质基础及其机制研究[D].陕西中医学院硕士学位论文：2-3.
[13] 谢元璋,孙蓉,张亚囡,等. 养血生发胶囊对小鼠急性毒性实验研究[J].中国药物警戒,2011,8(4):208-211.
[14] 杜晓曦.以非临床研究为起点的中药上市后研究方法的探索[J].中国药物警戒,2011,8(4):211.

[1]	GUO Ningzi, LIU Li, YUE Ruiqi, FENG Huiqing, YANG Huaxin, WEI Ningyi, CHEN Hua. Determination of particle size distribution of chiglitazar sodium by laser diffraction method [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 147-151.
[2]	ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.
[3]	ZHANG Bing, SA Rina, ZHANG Xiaomeng, ZHANG Dan, LIN Zhijian, WANG Yu. Research progress in pharmacogenic cardiotoxicity [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 841-847.
[4]	YANG Le, XIA Dongsheng, WANG Tao. Risks to safety of vitamin B₆ injection [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 791-794.
[5]	MENG Kangkang, LIU Saiyue. After-marketing safety of coenzyme Q10 for injection [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 795-798.
[6]	ZHU Lan, JIN Zhe, LIU Lihong, ZHONG Lumiao, LIUXiaojun. Risks of Kangfuxiaoyan suppository due to routes of administration [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 306-310.
[7]	YANG Le, XIA Dongsheng, WANG Tao. Risks to safety of vitamin B₂ injection [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1256-1258.
[8]	LIU Cuili, WU Chen, WANG Tao. Risks posed by misoprostol tablets used in obstetrics and gynecology [J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 999-1001.
[9]	MENG Kangkang, WANG Chunting, XIONG Weiyi. Safety of propranolol tablets for infantile hemangioma [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 749-751.
[10]	WU Chen, LIU Cuili, WANG Tao. Cardiovascular safety of haloperidol preparations [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1100-1102.
[11]	ZHAO Xuan, GUO Jing, REN Shuang, ZHEN Jiancun. Management and working modes of outpatient pharmacies amid routine COVID-19 epidemic prevention [J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 100-102.
[12]	YU Yi, HUANG Qianqian, XIAO Aili. Analysis of Safety Risks of Ginkgo Biloba Tablets and Other Oral Preparations [J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 678-682.
[13]	YU Yi, WANG Hui, LIU Hongliang, WANG Chunting. Analysis and Consideration on Risk of Sodium Aescinate for Injection [J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 174-177.
[14]	LIU Cuili, ZHU Lan, WANG Tao, WU Chen. Risks of Gastrodin Injection [J]. Chinese Journal of Pharmacovigilance, 2021, 18(10): 953-955.
[15]	ZHENG Xue, SI Jigang. Research Progress of Weight Gain Induced by Antidepressants [J]. Chinese Journal of Pharmacovigilance, 2020, 17(7): 444-447.